No Data
Remegen (9995.HK): A star in the ADC and fusion protein fields with a solid foundation and continuous innovation.
The company has three major technical platforms: Antibody-Drug Conjugates (ADC), fusion proteins, and bispecific antibodies. The Vedixitumab (Aidixi) launched in 2021 is the first domestically produced ADC, while the fusion protein Taitsipu (Tai Ai) is the world's first dual-target therapy.
[Brokerage Focus] Zhongtai International first gives remegen (09995) a "buy" rating, expects shareholder net losses to decrease year by year.
Jinwu Financial News | Zhongtai International's research report points out that remegen (09995) has three major technology platforms: antibody-drug conjugates (ADCs), fusion proteins, and bispecific antibodies. The first domestically produced ADC, the medication Vidisigimab (Aitesi), was launched in 2021, while the fusion protein Taitusimab (Tai'ai) is the world's first biopharmaceutical for the dual-target treatment of systemic lupus erythematosus. These two products are star products in the domestic oncology and autoimmune fields. The company has six drug candidates in development in the oncology and ophthalmology fields, indicating a strong research and development pipeline. The report states that the sales revenue of the company's first domestic ADC, Vidisigimab, will increase rapidly; Taitusimab stands to benefit from...
Express News | Remegen: Independent director Ma Lan resigns.
remegen (688331): The trend of narrowing losses is obvious, and the overseas clinical trial of RC18 is progressing smoothly.
On October 29, 2024, Remegen released the third-quarter financial report for 2024: The quarterly revenue for 2024Q3 was 0.467 billion yuan (+34.6% year-on-year, +13.6% quarter-on-quarter).
After the failure to list on the Star Market and the Hong Kong Stock Exchange, Tiange Interactive is now turning to the BSE, planning to reduce the amount of funds raised by nearly 80%.
After unsuccessful attempts to list on the star market and the Hong Kong Stock Exchange, Tianguangshi has set its sights on the BSE. However, the planned fundraising amount has decreased from the previous 1.59 billion yuan to 0.349 billion yuan. Tianguangshi currently does not have any products approved for listing. The recruitment of the in-process pipeline for the treatment of primary membranous nephropathy has completed Phase III clinical trials, with several other pipelines lagging behind, indicating that Tianguangshi will face the risk of dependence on a single product in the future.
[Brokerage Focus] Zhongtai Securities maintains a "shareholding" rating on remegen (09995), pointing out its significant improvement in quarterly profit growth rate compared to the same period last year and quarter-on-quarter.
Jinwu Finance News | Zhongtai Securities released its research report, noting that Remegen (09995) achieved a third-quarter revenue of 0.47 billion yuan, a growth of +34.6% compared to the same period last year; total revenue for January-September 2024 reached 1.21 billion yuan, a 57.10% year-on-year increase; net loss in the third quarter was 0.29 billion yuan, a 32.6% decrease in losses compared to the second quarter. The bank indicated that the high-quality academic research results of Taitsipuxi and Vedixituximab continue to be published in international societies and journals, accumulating evidence-based medicine to promote the continuous growth in domestic sales volume of the two major products, with revenue in the first three quarters showing steady and rapid growth, meeting expectations.20
No Data
No Data